Health Care

Insider trading at Ceribell shows routine tax‑planning sales by CFO Foehr and others, with no major impact on 2026 outlook.

David Wickersham’s latest bulk purchase of VSee Health shares signals insider confidence in its GoMyRx partnership, but investors should weigh the company’s volatile price and weak earnings before acting.

Insider buying signals at Silexion Therapeutics: Noy Shlomo’s steady share purchases and CEO‑level stakes hint at confidence in the RNAi pipeline, suggesting potential undervaluation and long‑term upside for investors.

Insider buying surge at Hims & Hers Health shows management confidence in a low‑priced stock amid earnings beats and regulatory scrutiny.

UnitedHealth insider sales hint at a cautious outlook: CEO sales, regulator pressure, and a falling stock trend reveal a mixed view on the company’s near‑term prospects.

Ardelyx CEO Michael Raab’s recent insider trades—buying 20,833 shares at $0.99 and selling 41,666 at $6.26—show disciplined liquidity management and long‑term confidence in the company’s growth strategy.

Insider buying spurs confidence in Cocrystal Pharma (CRP) as executives accumulate shares ahead of key norovirus data, suggesting a potential upside for investors.

Insightful look at Amylyx’s insider sales: Mazzariello’s tax‑withholding trades, their impact on stock, and what they reveal about the company’s future.

Planet 13 insider Wren Chris’s February 20 buy backs 30,000 shares at $0.17, signaling cautious confidence as the company pivots to core Nevada operations and refocuses after shedding California assets.

Insider buying fuels hope for Humana as shares slump 32.9% from the year’s high; steady purchases by CEO Shetty suggest undervaluation and growth potential.